Minogue Michael R's Form 4 filing
Abiomed Inc (ABMD) · filed Aug 25, 2021
- Accession no.
- 0001179110-21-008415
- Filed
- Aug 25, 2021
- Trade date
- Aug 23, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.22M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Minogue Michael RCIK 0001286370 | Director, Officer (Chairman, President, CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2021 | Common Stock $.01 par value | MOption exerciseAcquired | +3,492 | $23.15 | +$80,839.8 | 215,127 | Direct | |
| Aug 23, 2021 | Common Stock $.01 par value | SSaleDisposed | −3,492 | $350.00F7 | −$1,222,200 | 211,635 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2021 | Common stock | DReturned to the companyDisposed | −3,492 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F7
This price represents the sale price of the transactions on the reported date at $350.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.